These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 9257083

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B, Cappelaere P, Splinter T, Fabbro M, Wendling JL, Cals L, Catimel G, Giovannini M, Khayat D, Bastit P, Claverie N.
    Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
    Fauser AA, Duclos B, Chemaissani A, Del Favero A, Cognetti F, Diaz-Rubio E, Cortes-Funes H, Conte PF, Dressler H.
    Eur J Cancer; 1996 Aug; 32A(9):1523-9. PubMed ID: 8911112
    [Abstract] [Full Text] [Related]

  • 4. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
    Tan M, Xu R, Seth R.
    Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
    Coppes MJ, Yanofsky R, Pritchard S, Leclerc JM, Howard DR, Perrotta M, Keays S, Pyesmany A, Dempsey E, Pratt CB.
    J Pediatr Hematol Oncol; 1999 Jun; 21(4):274-83. PubMed ID: 10445889
    [Abstract] [Full Text] [Related]

  • 7. Palonosetron: in the prevention of nausea and vomiting.
    Yang LP, Scott LJ.
    Drugs; 2009 Nov 12; 69(16):2257-78. PubMed ID: 19852528
    [Abstract] [Full Text] [Related]

  • 8. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

  • 9. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE, Ettinger DS.
    Drugs; 1998 Feb 01; 55(2):173-89. PubMed ID: 9506240
    [Abstract] [Full Text] [Related]

  • 10. Ondansetron: a review of its use as an antiemetic in children.
    Culy CR, Bhana N, Plosker GL.
    Paediatr Drugs; 2001 Feb 01; 3(6):441-79. PubMed ID: 11437189
    [Abstract] [Full Text] [Related]

  • 11. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB.
    Clin Adv Hematol Oncol; 2004 May 01; 2(5):284-9. PubMed ID: 16163194
    [Abstract] [Full Text] [Related]

  • 12. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Rivière A, Khayat D, Bleiberg H, Faraldi M, Claverie N, Aranda E, Auclerc G, Audhuy B, Benhammouda A, Bleiberg H, Cals L, Cappelaere P, Cattan A, Cervantes A, Chevallier B, Conroy T, Cupissol D, De Grève J, Diaz-Rubio E, Seitz JF.
    Eur J Cancer; 1996 May 01; 32A(5):807-13. PubMed ID: 9081358
    [Abstract] [Full Text] [Related]

  • 13. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Pater JL, Lofters WS, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C.
    Ann Oncol; 1997 Feb 01; 8(2):181-5. PubMed ID: 9093728
    [Abstract] [Full Text] [Related]

  • 14. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
    Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C.
    J Clin Oncol; 1997 Aug 01; 15(8):2966-73. PubMed ID: 9256141
    [Abstract] [Full Text] [Related]

  • 15. Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
    Korttila K, Clergue F, Leeser J, Feiss P, Olthoff D, Payeur-Michel C, Wessel P, Nave S, Hahne W, Brown R.
    Acta Anaesthesiol Scand; 1997 Aug 01; 41(7):914-22. PubMed ID: 9265937
    [Abstract] [Full Text] [Related]

  • 16. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
    Diemunsch P, D'Hollander A, Paxton L, Schoeffler P, Wessel P, Navé S, Brown RA, Hahne WF.
    J Clin Anesth; 1997 Aug 01; 9(5):365-73. PubMed ID: 9257201
    [Abstract] [Full Text] [Related]

  • 17. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A.
    J Oncol Pharm Pract; 2007 Jun 01; 13(2):69-75. PubMed ID: 17873106
    [Abstract] [Full Text] [Related]

  • 18. Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group.
    Kovac AL, Scuderi PE, Boerner TF, Chelly JE, Goldberg ME, Hantler CB, Hahne WF, Brown RA.
    Anesth Analg; 1997 Sep 01; 85(3):546-52. PubMed ID: 9296407
    [Abstract] [Full Text] [Related]

  • 19. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W.
    J Clin Oncol; 1996 Aug 01; 14(8):2242-9. PubMed ID: 8708713
    [Abstract] [Full Text] [Related]

  • 20. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb 01; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.